A dose-finding Phase 2 study of single agent isatuximab (anti-CD38 mAb) in relapsed/refractory multiple myeloma
Open Access
- 14 May 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Leukemia
- Vol. 34 (12), 3298-3309
- https://doi.org/10.1038/s41375-020-0857-2
Abstract
A Phase 2 dose-finding study evaluated isatuximab, an anti-CD38 monoclonal antibody, in relapsed/refractory multiple myeloma (RRMM; NCT01084252). Patients with ≥3 prior lines or refractory to both immunomodulatory drugs and proteasome inhibitors (dual refractory) were randomized to isatuximab 3 mg/kg every 2 weeks (Q2W), 10 mg/kg Q2W(2 cycles)/Q4W, or 10 mg/kg Q2W. A fourth arm evaluated 20 mg/kg QW(1 cycle)/Q2W. Patients (N = 97) had a median (range) age of 62 years (38–85), 5 (2–14) prior therapy lines, and 85% were double refractory. The overall response rate (ORR) was 4.3, 20.0, 29.2, and 24.0% with isatuximab 3 mg/kg Q2W, 10 mg/kg Q2W/Q4W, 10 mg/kg Q2W, and 20 mg/kg QW/Q2W, respectively. At doses ≥10 mg/kg, median progression-free survival and overall survival were 4.6 and 18.7 months, respectively, and the ORR was 40.9% (9/22) in patients with high-risk cytogenetics. CD38 receptor density was similar in responders and non-responders. The most common non-hematologic adverse events (typically grade ≤2) were nausea (34.0%), fatigue (32.0%), and upper respiratory tract infections (28.9%). Infusion reactions (typically with first infusion and grade ≤2) occurred in 51.5% of patients. In conclusion, isatuximab is active and generally well tolerated in heavily pretreated RRMM, with greatest efficacy at doses ≥10 mg/kg.Keywords
Funding Information
- Sanofi (Not applicable, Not applicable, Not applicable, Not applicable, Not applicable, Not applicable, Not applicable, Not applicable, Not applicable, Not applicable, Not applicable, Not applicable, Not applicable)
This publication has 36 references indexed in Scilit:
- Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumabLeukemia, 2015
- Abstract 5092: Ziv-aflibercept treatment reduces intra-hepatic tumor growth of a preclinical colorectal carcinoma liver metastasis model, monitored using non-invasive micro-ultrasound and bioluminescent imaging.Published by American Association for Cancer Research (AACR) ,2014
- SAR650984, A Novel Humanized CD38-Targeting Antibody, Demonstrates Potent Antitumor Activity in Models of Multiple Myeloma and Other CD38+ Hematologic MalignanciesClinical Cancer Research, 2014
- U.S. Food and Drug Administration Approval: Carfilzomib for the Treatment of Multiple MyelomaClinical Cancer Research, 2013
- Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trialsPublished by Ferrata Storti Foundation (Haematologica) ,2013
- A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myelomaBlood, 2012
- Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1Blood, 2011
- Clinical Course of Patients With Relapsed Multiple MyelomaMayo Clinic Proceedings, 2004
- Flow Cytometric Immunophenotypic Analysis of 306 Cases of Multiple MyelomaAmerican Journal of Clinical Pathology, 2004
- Flow Cytometric Immunophenotypic Analysis of 306 Cases of Multiple MyelomaAmerican Journal of Clinical Pathology, 2004